Helen M. Thackray, M.D.

Helen M. Thackray, M.D.

Former Chief R&D OfficeratBiocryst Pharmaceuticals· In proxies 2021–2025

Pay in FY2025+22% from the year before · Biocryst Pharmaceuticals stock +3.7% the same year

Helen M. Thackray, M.D. was paid $4.3M in FY2025 (Dec), up 22%. Biocryst Pharmaceuticals stock rose 3.7% that year.

Pay$100 in the stock at the end of FY20 → $105
Pay is from the Summary Compensation Table of each Biocryst Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Biocryst PharmaceuticalsPublic company · 5 yr
    • Former Chief R&D Officer2021 – Present · 5 yrStock in role +15%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?